Breast
Featured Articles
(The Center For Biosimilars) Apr 23, 2018 - Pfizer announced this morning that the FDA has issued a Complete Response Letter (CRL) for PF-05280014, a proposed trastuzumab biosimilar referencing Herceptin.
Read Article
(Penn LDI) Apr 18, 2018 - Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer. One of the biggest drivers of this growth is targeted cancer drugs.
Read Article
Latest Articles
April 23, 2018
April 23, 2018
April 23, 2018
April 20, 2018
April 20, 2018
April 19, 2018
April 19, 2018
April 19, 2018
View More
News Commentary
Editor Image
27 Apr, 2017 | by Howard S. Hochster, MD
It is not difficult to imagine that PARP inhibitors, which function through the...
View Comment
Editor Image
26 May, 2017 | by
it's not more resistance to treatment ,but the anti her2 drugs probably don't...
View Comment
View More
OBR Green
There are no Breast OBR Green articles.
OBR Blog
By Jay Grisolano, PhD and Stephanie Ritz, PhD Approximately a quarter of breast cancer patients are classified as... Read more
June 05, 2017
By Liseth Parra, Ph.D., and Stephanie Hawthorne, Ph.D.   A very exciting therapeutic area that has been constantly... Read more
June 05, 2017